Skip to content
18 November · 06:30 UTCFollow AstraZeneca by emailFollow

AZN · story · 17 November – 18 November

AstraZeneca unit defeats Soliris monopolisation suit

AstraZeneca · 4 headlines from 4 outlets, from 17 November 2026 to 18 November 2026.

The story

+8.3strongly positive
Headlines4
Outlets4
Days217 November – 18 November

A lawsuit by an insurer alleging Soliris monopolisation was defeated.

The story's tone is the average of its headlines' own scores. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

How each outlet covered it · 4 outlets

Every outlet, by impact on the tone

Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone.

Source: MarketFrame news analysis

Every outlet, by impact on the tone. Average tone of each outlet's headlines in this story, −10 to +10. Impact = headlines × strength of tone. Source: MarketFrame news analysis
outletAverage tone
Life Sciences IP Review8.3
PYMNTS.com8.3
Reuters8.3
Bloomberg Law News8.3
OutletHeadlinesAverage tone
Life Sciences IP Review1+8.3
PYMNTS.com1+8.3
Reuters1+8.3
Bloomberg Law News1+8.3

One or two headlines is not a lean: read these as how this story was told, not as a verdict on the outlet.

Day by day · 2 days, strongest headlines first

Wednesday 18 November 20262 headlines · Reports say AstraZeneca's unit won dismissal of the Soliris antitrust lawsuit.+8.3
ToneWhat the article reported, and why it scored that waySource
+8.3Antitrust lawsuit over biosimilar delays thrown out in its favour.Life Sciences IP Review (opens the article) ↗
+8.3Court dismisses antitrust claim against the company.PYMNTS.com (opens the article) ↗
Tuesday 17 November 20262 headlines · A lawsuit by an insurer alleging Soliris monopolisation was defeated.+8.3
ToneWhat the article reported, and why it scored that waySource
+8.3Company avoids litigation over alleged market dominance of a drug.Reuters (opens the article) ↗
+8.3Subsidiary wins dismissal of insurer's competition claim.Bloomberg Law News (opens the article) ↗

Follow by email

A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.

How it works. Every morning an AI model reads the UK business news about each FTSE 100 company and scores how good or bad it is for the company, from −10 to +10. Pages update by about 07:45 UK time.

Not investment advice. MarketFrame rates the tone of news coverage. It is general information, not a recommendation to buy or sell anything. The scores are not share-price data or forecasts: a good score doesn't mean a share will rise, and a bad one doesn't mean it will fall.

Data to 06:30 UTC, 18 November · 867 headlines · 94 companiesMade by Adapt Progress Evolve Limited, a UK company · Privacy · Terms · Who we are · RSS · API · llms.txt